کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5586882 | 1568723 | 2017 | 6 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Increased interleukin-35 expression in tumor-infiltrating lymphocytes correlates with poor prognosis in patients with breast cancer
ترجمه فارسی عنوان
افزایش بیان اینترلوکین 35 در لنفوسیت های تومور نفوذی همراه با پیش آگهی ضعیف در بیماران مبتلا به سرطان پستان
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
EGFRhuman epithelial growth factor receptor 2IL-35EBI3HER2IDCTregsPFs - PF هاInterleukin-35 - اینترلوکین 35Bregs - برگزprogression-free survival - بقا بدون پیشرفتoverall survival - بقای کلTumor-infiltrating lymphocytes - تومور لنفوسیتها نفوذ می کندTILS - جریان بداخلNSCLC - سرطان ریوی غیر سلول کوچکNon-small cell lung cancer - سرطان غیر سلول کوچک ریهBreast cancer - سرطان پستانregulatory B cells - سلول های تنظیم کننده BRegulatory T cells - سلولهای تی تنظیمکنندهInvasive ductal carcinoma - کارسینوم مجرای تهاجمیEstrogen receptor - گیرنده استروژنEpidermal growth factor receptor - گیرنده فاکتور رشد اپیدرمالProgesterone receptor - گیرنده پروژسترون
موضوعات مرتبط
علوم زیستی و بیوفناوری
بیوشیمی، ژنتیک و زیست شناسی مولکولی
علوم غدد
چکیده انگلیسی
Interleukin-35 (IL-35) is a recently discovered inhibitory cytokine, which is firstly discovered to be produced by regulatory T cells (Tregs) and proposed as a key effector molecule of Treg function. This study aims to analyze the correlation between IL-35 expression in tumor-infiltrating lymphocytes (TILs) of breast cancer tissue and patients' clinical characteristics. Plasma IL-35 was also determined in 60 patients with breast invasive ductal carcinoma (IDC) and 30 healthy women by enzyme-linked immunosorbent assay. IL-35 expression in the tissue specimens was analyzed by immunohistochemistry. It was shown that 39.1%, 43.6% and 17.3% of the 110 patients were absent, weak, and strong IL-35 expression in the TILs, respectively. Strong IL-35 expression in TILs was significantly associated with age >50Â years, tumor size >2Â cm, TNM stage III, and negative ER (All PÂ <Â 0.05). Patients with elevated IL-35 expression in TILs had significantly worse progression-free survival (PFS) and overall survival (OS) than patients with weak or no IL-35 expression (All PÂ <Â 0.05). High plasma IL-35 levels were significantly associated with TNM stage III and lymph node metastasis (All PÂ <Â 0.05). Plasma IL-35 level and IL-35 expression in the TILs of breast cancer tissues may be a valuable biomarker in the development and prognosis of IDC.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Cytokine - Volume 89, January 2017, Pages 76-81
Journal: Cytokine - Volume 89, January 2017, Pages 76-81
نویسندگان
Zhonghua Zhao, Xi Chen, Shengnan Hao, Rui Jia, Nana Wang, Shaoshui Chen, Mianli Li, Chuanxin Wang, Haiting Mao,